(MD) Mednax - Overview
Sector: Healthcare | Industry: Medical Care Facilities | Exchange: NYSE (USA) | Market Cap: 1.746m USD | Total Return: 55.7% in 12m
Avg Turnover: 19.6M
EPS Trend: 81.4%
Qual. Beats: 0
Rev. Trend: -82.4%
Qual. Beats: 1
Warnings
Below Avwap Earnings
Tailwinds
No distinct edge detected
Pediatrix Medical Group (NYSE: MD) provides specialized physician services focusing on neonatal, maternal-fetal, and pediatric subspecialty care across the United States. The company operates primarily through affiliated clinicians who staff hospital-based neonatal intensive care units (NICUs) and provide outpatient care for high-risk pregnancies. Its service portfolio includes pediatric surgery, intensive care, and newborn hearing screening programs.
The business model relies on long-term contracts with hospital systems to provide essential, 24-hour clinical staffing for specialized departments. This sector is characterized by high barriers to entry due to the scarcity of board-certified subspecialists and the critical nature of acute neonatal care. Formerly known as MEDNAX, the company rebranded in 2022 to align its corporate identity with its core pediatric clinical operations.
Investors may find additional fundamental insights by reviewing the latest valuation metrics on ValueRay. Founded in 1979 and headquartered in Sunrise, Florida, the company remains a primary provider in the consolidated physician services market.
- Declining national birth rates reduce patient volume across core NICU service lines
- Managed care contract negotiations impact reimbursement rates and operating margins
- Labor cost inflation for specialized clinicians pressures hospital-based service profitability
- Regulatory changes to the No Surprises Act affect out-of-network revenue streams
- Hospital system consolidation shifts bargaining power and affects long-term service agreements
| Net Income: 174.2m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.11 > 0.02 and ΔFCF/TA 1.73 > 1.0 |
| NWC/Revenue: 7.48% < 20% (prev 11.16%; Δ -3.69% < -1%) |
| CFO/TA 0.13 > 3% & CFO 259.1m > Net Income 174.2m |
| Net Debt (339.7m) to EBITDA (279.0m): 1.22 < 3 |
| Current Ratio: 1.33 > 1.5 & < 3 |
| Outstanding Shares: last quarter (83.1m) vs 12m ago -3.19% < -2% |
| Gross Margin: 25.80% > 18% (prev 0.23%; Δ 2.56k% > 0.5%) |
| Asset Turnover: 95.07% > 50% (prev 99.13%; Δ -4.06% > 0%) |
| Interest Coverage Ratio: 8.78 > 6 (EBITDA TTM 279.0m / Interest Expense TTM 29.2m) |
| A: 0.07 (Total Current Assets 587.0m - Total Current Liabilities 442.6m) / Total Assets 2.07b |
| B: -0.03 (Retained Earnings -53.6m / Total Assets 2.07b) |
| C: 0.13 (EBIT TTM 256.4m / Avg Total Assets 2.03b) |
| D: -0.04 (Book Value of Equity -52.7m / Total Liabilities 1.19b) |
| Altman-Z'' = 1.17 = BB |
| DSRI: 0.96 (Receivables 237.0m/252.8m, Revenue 1.93b/1.98b) |
| GMI: 0.91 (GM 25.80% / 23.38%) |
| AQI: 0.95 (AQ_t 0.68 / AQ_t-1 0.71) |
| SGI: 0.98 (Revenue 1.93b / 1.98b) |
| TATA: -0.04 (NI 174.2m - CFO 259.1m) / TA 2.07b) |
| Beneish M = -3.23 (Cap -4..+1) = AA |
As of May 27, 2026, the stock is trading at USD 21.56 with a total of 540,565 shares traded.
Over the past week, the price has changed by -4.77%,
over one month by -7.82%,
over three months by +8.56% and
over the past year by +55.67%.
Mednax has received a consensus analysts rating of 3.75. Therefore, it is recommended to hold MD.
- StrongBuy: 3
- Buy: 0
- Hold: 5
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 23.2 | 7.5% |
P/E Trailing = 10.3204
P/E Forward = 8.2102
P/S = 0.9038
P/B = 1.9872
P/EG = 0.2433
Revenue TTM = 1.93b USD
EBIT TTM = 256.4m USD
EBITDA TTM = 279.0m USD
Long Term Debt = 398.3m USD (from longTermDebt, last quarter)
Short Term Debt = 204.3m USD (from shortTermDebt, last quarter)
Debt = 668.7m USD (from shortLongTermDebtTotal, last quarter) + Leases 38.9m
Net Debt = 339.7m USD (calculated: Debt 668.7m - CCE 329.0m)
Enterprise Value = 2.09b USD (1.75b + Debt 668.7m - CCE 329.0m)
Interest Coverage Ratio = 8.78 (Ebit TTM 256.4m / Interest Expense TTM 29.2m)
EV/FCF = 8.78x (Enterprise Value 2.09b / FCF TTM 237.7m)
FCF Yield = 11.40% (FCF TTM 237.7m / Enterprise Value 2.09b)
FCF Margin = 12.30% (FCF TTM 237.7m / Revenue TTM 1.93b)
Net Margin = 9.02% (Net Income TTM 174.2m / Revenue TTM 1.93b)
Gross Margin = 25.80% ((Revenue TTM 1.93b - Cost of Revenue TTM 1.43b) / Revenue TTM)
Gross Margin QoQ = 23.72% (prev 24.37%)
Tobins Q-Ratio = 1.01 (Enterprise Value 2.09b / Total Assets 2.07b)
Interest Expense / Debt = 4.37% (Interest Expense 29.2m / Debt 668.7m)
Taxrate = 23.87% (9.27m / 38.8m)
NOPAT = 195.2m (EBIT 256.4m * (1 - 23.87%))
Current Ratio = 1.33 (Total Current Assets 587.0m / Total Current Liabilities 442.6m)
Debt / Equity = 0.76 (Debt 668.7m / totalStockholderEquity, last quarter 878.6m)
Debt / EBITDA = 1.22 (Net Debt 339.7m / EBITDA 279.0m)
Debt / FCF = 1.43 (Net Debt 339.7m / FCF TTM 237.7m)
Total Stockholder Equity = 867.2m (last 4 quarters mean from totalStockholderEquity)
RoA = 8.57% (Net Income 174.2m / Total Assets 2.07b)
RoE = 18.92% (Net Income TTM 174.2m / Total Stockholder Equity 920.8m)
RoCE = 19.44% (EBIT 256.4m / Capital Employed (Equity 920.8m + L.T.Debt 398.3m))
RoIC = 12.80% (NOPAT 195.2m / Invested Capital 1.53b)
WACC = 5.61% (E(1.75b)/V(2.41b) * Re(6.48%) + D(668.7m)/V(2.41b) * Rd(4.37%) * (1-Tc(0.24)))
Discount Rate = 6.48% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 11.11 | Cagr: -0.50%
[DCF] Terminal Value 77.97% ; FCFF base≈220.3m ; Y1≈252.6m ; Y5≈371.7m
[DCF] Fair Price = 63.98 (EV 5.59b - Net Debt 339.7m = Equity 5.25b / Shares 82.1m; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: 81.39 | EPS CAGR: 21.04% | SUE: 0.78 | # QB: 0
Revenue Correlation: -82.40 | Revenue CAGR: -1.73% | SUE: 1.38 | # QB: 1
EPS current Quarter (2026-06-30): EPS=0.59 | Chg30d=-0.15% | Revisions=+20% | Analysts=7
EPS next Quarter (2026-09-30): EPS=0.67 | Chg30d=-2.34% | Revisions=-11% | Analysts=7
EPS current Year (2026-12-31): EPS=2.28 | Chg30d=+1.88% | Revisions=+40% | GrowthEPS=+11.6% | GrowthRev=+1.3%
EPS next Year (2027-12-31): EPS=2.36 | Chg30d=+1.43% | Revisions=+25% | GrowthEPS=+3.7% | GrowthRev=+2.5%
[Analyst] Revisions Ratio: +40%